501 related articles for article (PubMed ID: 18341607)
41. A survey of preventive measures among BRCA1 mutation carriers from Poland.
Gronwald J; Byrski T; Huzarski T; Cybulski C; Stawicka M; Szwiec M; Debniak T; Tulman A; Sun P; Oszurek O; Lubinski J; Narod SA
Clin Genet; 2007 Feb; 71(2):153-7. PubMed ID: 17250664
[TBL] [Abstract][Full Text] [Related]
42. Uptake of risk-reducing surgery in unaffected women at high risk of breast and ovarian cancer is risk, age, and time dependent.
Evans DG; Lalloo F; Ashcroft L; Shenton A; Clancy T; Baildam AD; Brain A; Hopwood P; Howell A
Cancer Epidemiol Biomarkers Prev; 2009 Aug; 18(8):2318-24. PubMed ID: 19661091
[TBL] [Abstract][Full Text] [Related]
43. Management updates for women with a BRCA1 or BRCA2 mutation.
Nusbaum R; Isaacs C
Mol Diagn Ther; 2007; 11(3):133-44. PubMed ID: 17570734
[TBL] [Abstract][Full Text] [Related]
44. Risk-reducing surgery in women with familial susceptibility for breast and/or ovarian cancer.
Antill Y; Reynolds J; Young MA; Kirk J; Tucker K; Bogtstra T; Wong S; Dudding T; Di Iulio J; Phillips KA
Eur J Cancer; 2006 Mar; 42(5):621-8. PubMed ID: 16434187
[TBL] [Abstract][Full Text] [Related]
45. Attitudes toward prophylactic oophorectomy and screening utilization in women at increased risk of developing hereditary breast/ovarian cancer.
Meiser B; Butow P; Barratt A; Friedlander M; Gattas M; Kirk J; Suthers G; Walpole I; Tucker K
Gynecol Oncol; 1999 Oct; 75(1):122-9. PubMed ID: 10502438
[TBL] [Abstract][Full Text] [Related]
46. Histopathological findings and follow-up after prophylactic mastectomy and immediate breast reconstruction in 100 women from families with hereditary breast cancer.
Isern AE; Loman N; Malina J; Olsson H; Ringberg A
Eur J Surg Oncol; 2008 Oct; 34(10):1148-54. PubMed ID: 18434071
[TBL] [Abstract][Full Text] [Related]
47. Morphology of breast cancer as a means of triage of patients for BRCA1 genetic testing.
Farshid G; Balleine RL; Cummings M; Waring P;
Am J Surg Pathol; 2006 Nov; 30(11):1357-66. PubMed ID: 17063074
[TBL] [Abstract][Full Text] [Related]
48. High risk for ovarian cancer in a prospective series is restricted to BRCA1/2 mutation carriers.
Maehle L; Apold J; Paulsen T; Hagen B; Løvslett K; Fiane B; Van Ghelue M; Clark N; Møller P
Clin Cancer Res; 2008 Nov; 14(22):7569-73. PubMed ID: 19010876
[TBL] [Abstract][Full Text] [Related]
49. Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy.
Lamb JD; Garcia RL; Goff BA; Paley PJ; Swisher EM
Am J Obstet Gynecol; 2006 Jun; 194(6):1702-9. PubMed ID: 16731090
[TBL] [Abstract][Full Text] [Related]
50. Parental origin of mutation and the risk of breast cancer in a prospective study of women with a BRCA1 or BRCA2 mutation.
Senst N; Llacuachaqui M; Lubinski J; Lynch H; Armel S; Neuhausen S; Ghadirian P; Sun P; Narod SA;
Clin Genet; 2013 Jul; 84(1):43-6. PubMed ID: 23066998
[TBL] [Abstract][Full Text] [Related]
51. Humoral immune responses to MUC1 in women with a BRCA1 or BRCA2 mutation.
Hermsen BB; Verheijen RH; Menko FH; Gille JJ; van Uffelen K; Blankenstein MA; Meijer S; van Diest PJ; Kenemans P; von Mensdorff-Pouilly S
Eur J Cancer; 2007 Jul; 43(10):1556-63. PubMed ID: 17532207
[TBL] [Abstract][Full Text] [Related]
52. A simulation model to predict the impact of prophylactic surgery and screening on the life expectancy of BRCA1 and BRCA2 mutation carriers.
Sigal BM; Munoz DF; Kurian AW; Plevritis SK
Cancer Epidemiol Biomarkers Prev; 2012 Jul; 21(7):1066-77. PubMed ID: 22556274
[TBL] [Abstract][Full Text] [Related]
53. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
54. Factors affecting genetic testing and decisions about prophylactic surgery.
Mahon SM
Clin J Oncol Nurs; 2001; 5(3):117-20. PubMed ID: 11899370
[TBL] [Abstract][Full Text] [Related]
55. Physicians' attitudes towards mammography and prophylactic surgery for hereditary breast/ovarian cancer risk and subsequently published guidelines.
Julian-Reynier C; Eisinger F; Moatti JP; Sobol H
Eur J Hum Genet; 2000 Mar; 8(3):204-8. PubMed ID: 10780786
[TBL] [Abstract][Full Text] [Related]
56. Twenty-three novel BRCA1 and BRCA2 sequence alterations in breast and/or ovarian cancer families of Eastern Spain.
Esteban Cardeñosa E; Bolufer Gilabert P; Palanca Suela S; Oltra Soler S; Barragán González E; Velasco Sampedro E; Chirivella González I; Segura Huerta A; Guillén Ponce C; Martínez de Dueñas E;
Breast Cancer Res Treat; 2008 Nov; 112(1):69-73. PubMed ID: 18060494
[TBL] [Abstract][Full Text] [Related]
57. [Present status and tasks for genetic testing and risk-reducing surgery in patients with hereditary breast and ovarian cancer].
Arai M; Taki K; Iwase H; Takizawa K; Nishimura S; Iwase T
Gan To Kagaku Ryoho; 2012 Apr; 39(4):525-31. PubMed ID: 22504676
[TBL] [Abstract][Full Text] [Related]
58. Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation.
Meijers-Heijboer EJ; Verhoog LC; Brekelmans CT; Seynaeve C; Tilanus-Linthorst MM; Wagner A; Dukel L; Devilee P; van den Ouweland AM; van Geel AN; Klijn JG
Lancet; 2000 Jun; 355(9220):2015-20. PubMed ID: 10885351
[TBL] [Abstract][Full Text] [Related]
59. Surgical procedure in patients with ovarian cancer diagnosed at the time of prophylactic oophorectomy. Analysis of two cases, literature review and surgical implications.
Morice P; Pautier P; Delaloge S; Spatz A; Chompret A
Eur J Obstet Gynecol Reprod Biol; 2004 Apr; 113(2):251-4. PubMed ID: 15063971
[TBL] [Abstract][Full Text] [Related]
60. Management of women with a family history of breast cancer.
Curry P; Fentiman IS
Int J Clin Pract; 1999; 53(3):192-6. PubMed ID: 10665131
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
